-
公开(公告)号：US20230322803A1
公开(公告)日：2023-10-12
申请号：US17913206
申请日：2021-03-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Andrew P. Degnan , Godwin Kwame Kumi , Andrew J. Tebben , Audris Huang , Peter Kinam Park , Donna M. Bilder , Emily Charlotte Cherney , Ashok Vinayak Purandare
IPC: C07D498/04 , C07D471/04 , C07D401/14
CPC classification number: C07D498/04 , C07D401/14 , C07D471/04
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
Patent Agency Ranking
公开(公告)号：US11066392B2
公开(公告)日：2021-07-20
申请号：US16612076
申请日：2018-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Liping Zhang , Audris Huang , Weifang Shan , David K. Williams , Xiao Zhu , Weiwei Guo
IPC: A61P35/00 , A61K31/444 , A61K31/4709 , A61K31/4375 , A61K31/497 , A61K31/506 , C07D401/12 , C07D403/12 , C07D471/04 , C07D213/85
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US10689331B2
公开(公告)日：2020-06-23
申请号：US15737798
申请日：2016-06-27
Applicant: Bristol-Myers Squibb Company
Inventor： James Aaron Balog , Emily Charlotte Cherney , Jay A. Markwalder , Weifang Shan , David K. Williams
IPC: A61K31/18 , A61K31/196 , A61K31/381 , A61K31/404 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/433 , A61K31/4406 , A61K31/505 , A61K31/513 , C07C275/42 , C07D239/42 , C07D261/14 , C07D285/12 , C07C311/51 , C07C311/49 , C07C275/40 , C07C233/44 , A61K45/06 , C07C311/46 , C07D209/08 , C07D213/72 , C07D239/47 , C07D257/04 , C07D263/32 , C07D277/38 , C07D285/135 , C07D333/34
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US10544099B2
公开(公告)日：2020-01-28
申请号：US16098260
申请日：2017-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Emily Charlotte Cherney , Liping Zhang , David K. Williams , James Aaron Balog
IPC: C07D215/18 , C07D215/233 , C07D401/04 , A61P35/00 , A61K31/47 , A61K31/4709 , A61K45/06
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09790169B2
公开(公告)日：2017-10-17
申请号：US15088211
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: C07C229/42 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C255/58 , C07C275/40 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D309/14 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20170231999A1
公开(公告)日：2017-08-17
申请号：US15584818
申请日：2017-05-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: A61K31/538 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K39/395 , A61K45/06
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
-
-
-
-
Search Results
16
records
(took 0.06 seconds)
